Newell Brands Invests €40 Million in French Operations, Driving Stock Gains
Money

Newell Brands Invests €40 Million in French Operations, Driving Stock Gains

authorBy Bola Sokunbi
DateJun 20, 2026
Read Time2 min

Newell Brands (NWL) has seen substantial positive momentum recently, largely driven by a significant €40 million investment strategy for its French operations and robust first-quarter earnings for fiscal year 2026. Trading at an attractive forward price-to-earnings ratio of approximately 7.6, notably below the sector average of 15.97, the company's stock has surged over 30% in the last month, reflecting growing investor confidence.

This strategic financial commitment will be allocated across four critical areas: advanced manufacturing automation, the integration of AI for digitization, sustainability and infrastructure enhancements, and comprehensive workforce development programs. France is a vital market for Newell, ranking among its top ten international markets, where the company has maintained a presence for over a century and employs close to 1,000 individuals. International sales constitute a considerable 39% of Newell's total revenue, underscoring the importance of this European expansion.

Newell Brands' strong performance in Q1 2026, with reported revenues of $1.55 billion surpassing expectations, further validates its strategic direction. The Learning & Development division was a key growth driver, expanding by 3.8% to reach $594 million. Bolstered by these results, management has revised its full-year 2026 projections, anticipating normalized earnings per share between $0.56 and $0.60 and net sales growth ranging from flat to a 2% increase. The company's diverse portfolio of well-known consumer brands, including Rubbermaid, Sharpie, and Yankee Candle, positions it strongly for continued market leadership and innovation.

Newell Brands' strategic investments and solid financial performance illustrate a company actively pursuing growth and innovation, signaling a positive trajectory for its market position and future profitability. This proactive approach not only strengthens its operational capabilities but also enhances its competitive edge in a dynamic global market, promising sustained value for shareholders.

More Articles
Money
On the Border Mexican Grill & Cantina Enters Chapter 7 Liquidation
On the Border, a Mexican casual dining chain, has officially filed for Chapter 7 bankruptcy, leading to the liquidation of its company-owned locations. This move follows an initial Chapter 11 filing and a brief acquisition by Pappas Restaurant Group, which ultimately withdrew its investment. The company cited ongoing financial struggles, including underperforming leases and rising operational costs, as key factors in its demise. Franchise locations remain operational, while the brand's assets are now subject to sale.
By Natalie PaceJun 20, 2026
Money
Clarivate Plc Appoints Simon Webster as President of Intellectual Property Segment
Clarivate Plc (NYSE:CLVT) has announced the appointment of Simon Webster as President of its Intellectual Property segment, effective June 10, 2026. Webster, who previously led CPA Global before its merger with Clarivate, brings extensive experience and familiarity with the IP business. He replaces Maroun S. Mourad, with a transition period extending through September. The company plans to focus on AI-enhanced intelligence, improved sales execution, and disciplined operations within the IP segment, while reaffirming its full-year 2026 financial outlook of $2.30 billion to $2.42 billion in revenue and adjusted EPS of $0.70 to $0.80.
By T. Harv EkerJun 20, 2026
Money
Precigen Gains FDA Orphan Drug Exclusivity for PAPZIMEOS
Precigen Inc. (PGEN) has secured FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine targeting recurrent respiratory papillomatosis (RRP). This designation grants market exclusivity until August 2032, preventing similar treatments from being approved. PAPZIMEOS, developed using Precigen's AdenoVerse platform, aims to reduce the need for frequent surgeries in RRP patients by training the immune system to combat HPV 6 and 11. Long-term clinical data showcased its sustained effectiveness, with most responders remaining surgery-free for extended periods.
By Chika UwazieJun 20, 2026
Money
Ultrapar Participações: A Deep Dive into an Undervalued Stock Under $5
Ultrapar Participações S.A. (UGP) has seen over 22% growth in the past six months, trading at an attractive forward P/E of 8.8. The Canada Pension Plan Investment Board recently acquired a 4.94% stake, highlighting its investment potential without seeking management control. The company's Q1 2026 earnings showed strong adjusted EPS and increased fuel distribution, signaling market recovery and operational efficiency.
By Scott PapeJun 20, 2026
Money
Pagaya Secures Upsized $800 Million Personal Loan ABS Transaction
Pagaya Technologies Ltd. (PGY) successfully closed an oversubscribed $800 million AAA-rated personal loan asset-backed securities (ABS) deal, PAID 2026-4. This transaction attracted 39 institutional investors and marks the third upsized personal loan ABS deal for Pagaya this year, bringing its total year-to-date issuance to nearly $4 billion. The achievement underscores the company's robust funding platform and investor confidence, despite a recent decline in billionaire holdings.
By JL CollinsJun 20, 2026